CA53272L2021 - Common Stock
LIMINAL BIOSCIENCES INC
NASDAQ:LMNL (9/25/2023, 7:00:18 PM)
8.5
+0.01 (+0.12%)
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
LIMINAL BIOSCIENCES INC
231 Dundas Street East
Belleville ONTARIO H7V 4B4
P: 14507810115.0
CEO: Bruce Pritchard
Employees: 43
Website: https://liminalbiosciences.com/
/PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" of de "Vennootschap") heeft het genoegen bekend te maken dat het de definitieve...
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) (« Liminal BioSciences » ou la « Société »), a le plaisir d'annoncer qu'elle a reçu l'ordonnance finale...
/PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) („Liminal BioSciences" oder das „Unternehmen") gibt bekannt, dass es die endgültige Verfügung des...
Liminal BioSciences (LMNL) said Tuesday it has received the Ontario Superior Court of Justice's final order for Structured Alpha LP to acquire all outstanding shares of the company it...
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the...
/CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the...
Here you can normally see the latest stock twits on LMNL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: